LALPATHLAB2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2020-10-012020-12-31in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member LALPATHLAB2020-10-012020-12-31in-bse-fin:FourOperatingExpenses02Member LALPATHLAB2020-10-012020-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2020-10-012020-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2020-10-012020-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LALPATHLAB2020-10-012020-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2020-04-01 2021-03-31 2021-01-18 INR Millions Third quarter Single segment the business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2020-10-01 2020-12-31 Unaudited Consolidated 4524000000.00 135000000.00 4659000000.00 1098000000.00 0.00 0.00 693000000.00 39000000.00 195000000.00 1345000000.00 3370000000.00 1289000000.00 0.00 1289000000.00 336000000.00 -6000000.00 330000000.00 0.00 959000000.00 0.00 0.00 0.00 0.00 959000000.00 0.00 959000000.00 945000000.00 14000000.00 945000000.00 14000000.00 833000000.00 10 11.44 11.41 0.00 0.00 11.44 11.41 0.00 0.00 0.00 1.tThe above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 29 January, 2021 respectively. n2.tThe above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). n3.tThese financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 '' Interim Financial Reporting'' (''IND AS 34''), prescribed under 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. n4.tThe Board of Directors of the Parent Company had approved first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 6 November, 2020 which has been paid during the quarter ended on 31 December, 2020. n nThe Board of Directors of the Parent Company have approved second interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 29 January, 2021. n n5.tSubsequent to the quarter and nine months ended 31 December, 2020, pursuant to the approval, the Board of Directors of PathLabs Unifiers Private Limited ( PUPL ), (a wholly owned subsidiary), acquired an equity stake of 70% in Chanre Laboratory Private Limited engaged in pathology business for a purchase consideration of INR 175 million. n6.tDuring the quarter and nine months ended 31 December, 2020, pursuant to approval of the Board of Directors of PathLabs Unifiers Private Limited ( PUPL ), (a wholly owned subsidiary), PUPL has purchased the business of Bindish Diagnostic Laboratory LLP ( BDL ) engaged in the business of providing pathological diagnostic services in Jamnagar, Gujarat on a going concern basis for a purchase consideration not exceeding INR 40 million for which the business purchase agreement was signed on 1 December, 2020. n7.tThe Board of Directors of the Parent Company and one of the subsidiary company's 'APL Institute of Clinical Laboratory & Research Private Limited' ( APL ), in their respective meetings held on 3 February, 2020 have approved the “Scheme of Amalgamation” of APL with the Parent Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Parent Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals. n8.tThe Board of Directors of the Parent Company in their meeting held on 13 August, 2019, had approved the closure of Dr. Lal PathLabs International BV, Netherlands a subsidiary, pursuant to which it was liquidated on October 20, 2020. n9.tThe Board of Directors of the Group, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore, there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. n10.tThe Indian Parliament has approved the Code on Social Security, 2020 (‘the Code’) which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified and the rules for quantifying the financial impact are also yet to be issued. In view of this, the impact of the change, if any, will be assessed and recognised post notification of the relevant provisions. Single segment 2020-04-01 2020-12-31 Unaudited Consolidated 11503000000.00 378000000.00 11881000000.00 2940000000.00 0.00 0.00 1976000000.00 116000000.00 569000000.00 3444000000.00 9045000000.00 2836000000.00 0.00 2836000000.00 765000000.00 -43000000.00 722000000.00 0.00 2114000000.00 0.00 0.00 0.00 0.00 2114000000.00 0.00 2114000000.00 2082000000.00 32000000.00 2082000000.00 32000000.00 833000000.00 10 25.23 25.16 0.00 0.00 25.23 25.16 0.00 0.00 0.00 Fees to collection centers/channel partners 604000000.00 Other expenses 741000000.00 Fees to collection centers/channel partners 1458000000.00 Other expenses 1986000000.00